XTX Topco Ltd Buys Shares of 32,682 Protara Therapeutics, Inc. (NASDAQ:TARA)

XTX Topco Ltd purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 32,682 shares of the company’s stock, valued at approximately $60,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TARA. Marshall Wace LLP purchased a new stake in Protara Therapeutics in the 2nd quarter valued at approximately $161,000. Renaissance Technologies LLC boosted its stake in shares of Protara Therapeutics by 77.8% in the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock valued at $313,000 after buying an additional 65,800 shares in the last quarter. Oppenheimer & Co. Inc. grew its holdings in Protara Therapeutics by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock worth $328,000 after acquiring an additional 51,944 shares during the period. CVI Holdings LLC acquired a new position in Protara Therapeutics during the second quarter worth $630,000. Finally, Armistice Capital LLC purchased a new position in Protara Therapeutics in the second quarter worth $1,082,000. 38.13% of the stock is currently owned by hedge funds and other institutional investors.

Protara Therapeutics Stock Up 4.1 %

Shares of TARA stock opened at $5.39 on Monday. The stock has a market cap of $111.20 million, a P/E ratio of -1.91 and a beta of 1.78. Protara Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The business has a fifty day simple moving average of $3.25 and a 200-day simple moving average of $2.50.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). On average, sell-side analysts anticipate that Protara Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analyst Weigh In

TARA has been the subject of a number of research analyst reports. Guggenheim reiterated a “buy” rating and issued a $20.00 price target on shares of Protara Therapeutics in a report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.